GeneMedicine

What GeneMedicine does

GeneMedicine (진메디신) is a clinical-stage South Korean biopharmaceutical company founded in 2014 by Professor Chae-Ok Yun of Hanyang University to develop next-generation oncolytic adenovirus therapies for solid tumors. The company is headquartered at Hanyang University's Fusion Technology Center in Seoul and operates a 4,300 sqm GMP manufacturing facility (the Hanam GT Plant, completed August 2022) that produces adenovirus, lentivirus, vaccinia, and herpes virus products. GeneMedicine is led by a team of approximately 35 specialized personnel covering the full drug development cycle from process development through regulatory affairs and business development. The company targets indications with significant unmet need including triple-negative breast cancer, pancreatic cancer, liver cancer, lung cancer, ovarian cancer, melanoma, and kidney cancer, with selected programs expanding into CNS diseases via an intranasal delivery platform.

GeneMedicine's core technology is the GM-oAd platform — oncolytic adenovirus coated with proprietary non-immunogenic nano-materials that enable systemic intravenous administration by evading immune system recognition. This is complemented by the PPE/PCION systemic delivery platforms, a local delivery enhancement drug delivery system, an extracellular matrix degradation technology for improved tumor penetration, and the GM201 intranasal DDS platform that bypasses the blood-brain barrier for brain disease therapeutics. The proprietary pipeline comprises four candidates: GM101 (completed Phase 1 in triple-negative breast cancer, Phase 2 preparation), GM102 (systemic delivery candidate for pancreatic cancer, Phase 1 preparation), GM103 (angiogenesis-inhibiting oncolytic adenovirus in Phase 1/2 for metastatic liver and lung cancers with both MFDS and FDA IND approvals), and GM104 (solid tumor candidate). The portfolio is protected by 160+ patents globally and 146 registered patents in Korea.

GeneMedicine operates a hybrid business model combining long-term proprietary drug development (with planned commercialization of GM101–GM104 and GM201) with near-term CDMO/CMO services and technology licensing. CDMO services are quote-based B2B contracts priced per project scope and scale, primarily serving global AAV and gene therapy developers facing viral vector capacity shortages. Technology licensing — exemplified by the Celltrion co-development agreement for systemic delivery platform technology and the WuXi ATU manufacturing agreement — provides milestone and royalty upside. Distribution is direct enterprise sales targeting large pharmaceutical and biotech companies globally. The company is preparing for a KOSDAQ listing with technical evaluation submission planned for H2 2026, and has raised approximately 838 billion KRW across Series A (165B in 2019), Series B (341B in 2021), Series B Plus (200B in 2023), and Series C (132B in 2024).

Name

GeneMedicine

Legal name

진메디신 주식회사

Website

https://gene-medicine.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

GeneMedicine is a clinical-stage South Korean biopharmaceutical company developing proprietary oncolytic adenovirus immunotherapies (GM101, GM102, GM103, GM104) and intranasal brain delivery platforms for solid tumors and CNS diseases, operating a dedicated GMP manufacturing facility and CDMO services.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)

akta.pro secondary industries

Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)

Keywords

• Oncolytic virus therapy
• Gene therapy manufacturing
• Viral vector CDMO
• Anticancer biopharmaceuticals
• Systemic drug delivery

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

1. CDMO Services: Contract development and manufacturing organization services for gene therapy products including AAV, lentivirus, vaccinia virus, and herpes virus. Short-term revenue model.
2. Technology Licensing: Licensing of proprietary platform technologies (systemic delivery, local delivery, brain delivery) to pharmaceutical and biotech companies
3. Drug Development & Commercialization: Long-term revenue from proprietary drug pipeline (GM101, GM102, GM103, GM104) development and eventual commercialization

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

GeneMedicine is a clinical-stage biopharmaceutical company developing next-generation oncolytic adenovirus-based cancer therapeutics (pipeline candidates GM101–GM104) and proprietary drug delivery platforms spanning systemic, local, and intranasal routes of administration. The company also operates a BSL-2 GMP viral vector Contract Development and Manufacturing Organization (CDMO) serving gene and cell therapy developers, providing near-term revenue alongside its drug development pipeline.

Product overview

GeneMedicine is a clinical-stage biotech company developing next-generation oncolytic adenovirus-based cancer therapeutics and drug delivery platforms. The product portfolio consists of four pipeline products (GM101, GM102, GM103, GM104) targeting various solid tumors, with GM103 in Phase 1/2 clinical trials and others in advanced stages. The company has developed multiple platform technologies including the GM-oAd (oncolytic adenovirus) platform, systemic delivery platforms (PPE/PCION), local delivery platform, and intranasal DDS platform for brain diseases. Beyond R&D, GeneMedicine operates a CDMO/CMO business offering gene therapy manufacturing services, having constructed a 4,300㎡ facility in Hanam, Gyeonggi Province. The company has strategic partnerships with Celltrion for systemic delivery platform co-development and WuXi ATU for manufacturing.

Differentiator

Problem solved

Functional benefit

Products and services

• GM101 Pipeline oncolytic adenovirus therapeutic candidate targeting triple-negative breast cancer (TNBC); intended for patients with refractory TNBC where conventional therapies have limited efficacy.
• GM102 Systemic delivery oncolytic adenovirus candidate for pancreatic cancer, addressing dense stromal barriers using the company's proprietary systemic delivery technology (PPE/PCION).
• GM103 Angiogenesis-inhibiting oncolytic adenovirus candidate designed to target tumors by inhibiting angiogenic pathways, advancing through Phase 1/2 clinical trials under MFDS and FDA IND approvals.
• GM104 Pipeline oncolytic adenovirus candidate for solid tumors, leveraging the company's GM-oAd platform with nano-material coating for immune evasion and systemic administration capability.
• GM-oAd Platform Proprietary oncolytic adenovirus platform featuring nano-material coating technology for immune evasion and selective tumor targeting; licensed or partnered as a platform offering to pharmaceutical collaborators.
• Systemic Delivery Platform (PPE / PCION) Proprietary systemic drug delivery platform combining PPE (extracellular matrix degradation) and PCION (tumor cell-specific targeting) technologies to enable systemic administration of oncolytic adenoviruses, addressing a major limitation in cancer virotherapy.
• Local Delivery Enhancement DDS Proprietary local drug delivery enhancement platform for direct intratumoral injection of oncolytic adenoviruses, optimized for tumor penetration and retention at the site of administration.
• GM201 Intranasal DDS Proprietary intranasal drug delivery system (IN-DDS) using GM201 to cross the blood-brain barrier non-invasively, supporting brain-targeted therapeutic applications.
• CDMO Services (Viral Vector Manufacturing) Contract Development and Manufacturing Organization services providing BSL-2 GMP-compliant viral vector manufacturing for gene and cell therapy developers requiring specialized adenovirus production capacity.

Quantifiable outcome

• Viral replication produces 10,000 to 100,000 new virus particles per infected cell, spreading through tumors in domino-like manner
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators9 records

Recent moves2 records

Expansion highlights6 records

Direct peers

• SillaJen: Korean clinical-stage biotech developing Pexa-Vec (oncolytic vaccinia virus) for hepatocellular carcinoma and other solid tumors. Directly comparable as an Asian oncolytic virus developer with later-stage clinical assets.
• CG Oncology: US-headquartered, KOSDAQ-dual-listed biotech developing oncolytic immunotherapy (cretostimogene) for bladder cancer. Comparable as an oncolytic virus developer with clinical-stage assets and Korean capital market exposure.
• PsiOxus Therapeutics: UK-based clinical-stage biotech developing oncolytic virus platforms (e.g., enadenotucirev) for systemic administration in solid tumors. Direct comparison to GeneMedicine's GM-oAd systemic delivery approach and similar clinical-stage positioning.
• Replimune: US/UK clinical-stage biotech developing a portfolio of oncolytic virus products (RP1, RP2, RP3) for solid tumors. Comparable as a platform-focused oncolytic virus developer with multiple clinical assets.
• DNAtrix: US-based clinical-stage biotech developing oncolytic virus therapies, with a particular focus on brain tumors. Highly relevant given GeneMedicine's GM201 intranasal brain delivery platform targeting CNS indications.
• Targovax: Norwegian clinical-stage biotech developing oncolytic virus therapies (ONCOS-102) engineered with GM-CSF for solid tumors. Comparable as a platform-based oncolytic virus developer targeting immune-cold tumors.
• Oncolytics Biotech: Canadian clinical-stage biotech developing pelareorep, an intravenously delivered oncolytic virus for breast cancer and other solid tumors. Direct comparison to GeneMedicine's systemic delivery positioning.

Broad incumbents

• Amgen: Global biopharmaceutical leader with Imlygic (talimogene laherparepvec), the only FDA-approved oncolytic virus therapy. Sets the commercial reference point and competitive benchmark for the entire field.
• WuXi Advanced Therapies: Global viral vector and gene therapy CDMO with which GeneMedicine has a manufacturing partnership. Sets the scale and quality benchmark for gene therapy CDMO services that GeneMedicine competes against through its Hanam facility.

Emerging players

• Vyriad: US-based clinical-stage biotech developing oncolytic vesicular stomatitis virus (VSV) platforms. Comparable as an emerging player in the systemic oncolytic virus delivery space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance11 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GeneMedicine